Written by Mario Rottorf, Helen Cooke and the CAM-Cancer Consortium.
Updated June 21, 2016

Coenzyme Q10

Does it work?

Adjuvant therapy

Controlled clinical studies

A two-arm, non-randomised trial compared the effects of CoQ10 (400mg/d, oral) on the recurrence rate in melanoma patients (n=81) who received three years of adjuvant therapy with recombinant IFNα-2b and CoQ10 versus no adjuvant therapy 30. In the CoQ10 treatment group, the recurrence rate was significantly lower after 5 years of follow-up. The quality of the data was not good, however, and there is a great risk of bias due to the lack of randomisation and the small patient sample.

Does CoQ10 work as a protector against adverse effects of chemotherapeutic agents?


A systematic review analysed the issue of whether oral administration of CoQ10 improved the tolerability of chemotherapy and reduced adverse events and toxicity 31. The review examined five controlled interventional studies in which patients with different malignant haematological systemic diseases or solid tumours were given CoQ10 at doses of 90-240mg/d concomitantly with anthracycline chemotherapy. Three of the five studies reported positive effects on surrogate parameters of cardiac function. The authors of the review regarded this as potential evidence of CoQ10 reducing the cardiotoxicity of anthracycline chemotherapeutic agents. However, they also determined the risk of bias in the studies to be very high, thus greatly limiting the strength of the findings.

Controlled clinical trials

A two-arm, randomised, double-blind, placebo-controlled study examined the effect of CoQ10 on chronic fatigue and health-related quality of life in 236 breast cancer patients 4. The intervention group received oral CoQ10 (300mg/d) for 24 weeks. There was no difference between the CoQ10 and placebo groups with regard to fatigue and quality of life. The risk of bias here is seen as low.

The aforementioned two-arm non-randomised trial in melanoma patients had as secondary endpoints the effects of CoQ10 on adverse effects of interferon (IFNα-2b). 30 The subjective rating by the treatment group (IFNα-2b + CoQ10) stated that there was a significant difference in the rate of adverse effects (such as fatigue or weakness), which occurred not at all or only in a mild form in comparison with the non-treatment group. Since the study was not blinded, there is a high risk of bias in these findings.


Mario Rottorf, Helen Cooke, CAM-Cancer Consortium. Coenzyme Q10 [online document]. http://www.cam-cancer.org/The-Summaries/Dietary-approaches/Coenzyme-Q10. June 21, 2016.

Document history

Revised in September 2016 by Mario Rottorf and Helen Cooke
Assessed as up to date in April 2014 by Barbara Wider.
Revised and updated in December 2012 by Helen Cooke.
Fully revised and updated in September 2011 by Helen Cooke.
Fully revised and updated in August 2009 by Helen Cooke.
First published in 2005, authored by Helen Seers and Helen Cooke.


  1. da Silva MC, Mendonca LM, Venancio VP, Bianchi ML, Antunes LM: Coenzyme Q10 protects Pc12 cells from cisplatin-induced DNA damage and neurotoxicity. Neurotoxicology 2013; 36:10-16.
  2. National Cancer Institute (NIH). PDQ Cancer Complementary and Alternative Medicine Editorial Board: Coenzyme Q10 (PDQ®) – Health Professional Version [online document]. Last updated on 21 April 2016. http://www.cancer.gov/about-cancer/treatment/cam/hp/coenzyme-q10-pdq. Accessed on 2 March 2016.
  3. Garrido-Maraver J, Cordero MD, Oropesa-Avila M, Fernandez VA, de la MM, Delgado PA, de MM, Perez CC, Villanueva PM, Cotan D, Sanchez-Alcazar JA: Coenzyme q10 therapy. Mol Syndromol 2014; 5(3-4):187-197.
  4. Lesser GJ, Case D, Stark N, Williford S, Giguere J, Garino LA, Naughton MJ, Vitolins MZ, Lively MO, Shaw EG: A Randomized, Double-Blind, Placebo-Controlled Study of Oral Coenzyme Q(10) to Relieve Self-Reported Treatment-Related Fatigue in Newly Diagnosed Patients with Breast Cancer. J Support Oncol 2013; 11(1):31-42.
  5. Potgieter M, Pretorius E, Pepper MS: Primary and secondary coenzyme Q10 deficiency: the role of therapeutic supplementation. Nutr Rev 2013; 71(3):180-188.
  6. MVZ Labor Ravensburg: Leistungsverzeichnis des MVZ Labor Ravensburg Dr. Gärtner - Coenzym Q10 (Ubichinon) [online document], 20 February 2009. http://leistungsverzeichnis.labor-gaertner.de/Entry/271. Accessed on 17 March 2016.
  7. Folkers K, Osterborg A, Nylander M, Morita M, Mellstedt H: Activities of vitamin Q10 in animal models and a serious deficiency in patients with cancer. Biochem Biophys Res Commun 1997; 234(2):296-299.
  8. Pepping J: Coenzyme Q10. Am J Health Syst Pharm 1999; 56(6):519-521.
  9. Cluis CP, Pinel D, Martin VJ: The production of coenzyme Q10 in microorganisms. Subcell Biochem 2012; 64:303-326.
  10. Lockwood K, Moesgaard S, Folkers K: Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10. Biochem Biophys Res Commun 1994; 199(3):1504-1508.
  11. Lockwood K, Moesgaard S, Yamamoto T, Folkers K: Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. Biochem Biophys Res Commun 1995; 212(1):172-177.
  12. Rusciani L, Proietti I, Rusciani A, Paradisi A, Sbordoni G, Alfano C, Panunzi S, De GA, Lippa S: Low plasma coenzyme Q10 levels as an independent prognostic factor for melanoma progression. J Am Acad Dermatol 2006; 54(2):234-241.
  13. Cooney RV, Dai Q, Gao YT, Chow WH, Franke AA, Shu XO, Li H, Ji B, Cai Q, Chai W, Zheng W: Low plasma coenzyme Q(10) levels and breast cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev 2011; 20(6):1124-1130.
  14. Chai W, Cooney RV, Franke AA, Shvetsov YB, Caberto CP, Wilkens LR, Le ML, Henderson BE, Kolonel LN, Goodman MT: Plasma coenzyme Q10 levels and postmenopausal breast cancer risk: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 2010; 19(9):2351-2356.
  15. El-Sheikh AAK, Morsy MA, Mahmoud MM, Rifaai RA, Abdelrahman AM: Effect of coenzyme-q10 on Doxorubicin-induced nephrotoxicity in rats. Adv Pharmacol Sci 2012; 2012:981461.
  16. Sachdanandam P: Antiangiogenic and hypolipidemic activity of coenzyme Q10 supplementation to breast cancer patients undergoing Tamoxifen therapy. Biofactors 2008; 32(1-4):151-159.
  17. Folkers K, Shizukuishi S, Takemura K, Drzewoski J, Richardson P, Ellis J, Kuzell WC: Increase in levels of IgG in serum of patients treated with coenzyme Q10. Res Commun Chem Pathol Pharmacol 1982; 38(2):335-338.
  18. Barbieri B, Lund B, Lundstrom B, Scaglione F: Coenzyme Q10 administration increases antibody titer in hepatitis B vaccinated volunteers--a single blind placebo-controlled and randomized clinical study. Biofactors 1999; 9(2-4):351-357.
  19. Folkers K, Hanioka T, Xia LJ, McRee JT, Jr., Langsjoen P: Coenzyme Q10 increases T4/T8 ratios of lymphocytes in ordinary subjects and relevance to patients having the AIDS related complex. Biochem Biophys Res Commun 1991; 176(2):786-791.
  20. Frei B, Kim MC, Ames BN: Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations. Proc Natl Acad Sci U S A 1990; 87(12):4879-4883.
  21. Shinozawa S, Gomita Y, Araki Y: Protective effects of various drugs on adriamycin (doxorubicin)-induced toxicity and microsomal lipid peroxidation in mice and rats. Biol Pharm Bull 1993; 16(11):1114-1117.
  22. Chandran K, Aggarwal D, Migrino RQ, Joseph J, McAllister D, Konorev EA, Antholine WE, Zielonka J, Srinivasan S, Avadhani NG, Kalyanaraman B: Doxorubicin inactivates myocardial cytochrome c oxidase in rats: cardioprotection by Mito-Q. Biophys J 2009; 96(4):1388-1398.
  23. Chen PY, Hou CW, Shibu MA, Day CH, Pai P, Liu ZR, Lin TY, Viswanadha VP, Kuo CH, Huang CY: Protective effect of Co-enzyme Q10 On doxorubicin-induced cardiomyopathy of rat hearts. Environ Toxicol 2016. doi: 10.1002/tox.22270
  24. Fouad AA, Al-Sultan AI, Refaie SM, Yacoubi MT: Coenzyme Q10 treatment ameliorates acute cisplatin nephrotoxicity in mice. Toxicology 2010; 274(1-3):49-56.
  25. Werbach MR: Nutritional strategies for treating chronic fatigue syndrome. Altern Med Rev 2000; 5(2):93-108.
  26. Nicolson GL: Mitochondrial Dysfunction and Chronic Disease: Treatment With Natural Supplements. Integr Med (Encinitas) 2014; 13(4):35-43.
  27. Molassiotis A, Scott JA, Kearney N, Pud D, Magri M, Selvekerova S, Bruyns I, Fernandez-Ortega P, Panteli V, Margulies A, Gudmundsdottir G, Milovics L, Ozden G, Platin N, Patiraki E: Complementary and alternative medicine use in breast cancer patients in Europe. Support Care Cancer 2006; 14(3):260-267.
  28. European Nutraceutical Association (ENA): Nutrazeutika in der ärztlichen Praxis - Mit besonderer Berücksichtigung der arztrechtlichen Situation in Deutschland [online document]. First edition released 2013. http://enaonline.org/files/artikel/319/Nutraceuticals%20in%20der%20aerztlichen%20PraxisWEB.pdf Accessed on 21 April 2016
  29. Tran MT, Mitchell TM, Kennedy DT, Giles JT: Role of coenzyme Q10 in chronic heart failure, angina, and hypertension. Pharmacotherapy 2001; 21(7):797-806.
  30. Rusciani L, Proietti I, Paradisi A, Rusciani A, Guerriero G, Mammone A, De GA, Lippa S: Recombinant interferon alpha-2b and coenzyme Q10 as a postsurgical adjuvant therapy for melanoma: a 3-year trial with recombinant interferon-alpha and 5-year follow-up. Melanoma Res 2007; 17(3):177-183.
  31. Roffe L, Schmidt K, Ernst E: Efficacy of coenzyme Q10 for improved tolerability of cancer treatments: a systematic review. J Clin Oncol 2004; 22(21):4418-4424.
  32. Mizuno K, Tanaka M, Nozaki S, Mizuma H, Ataka S, Tahara T, Sugino T, Shirai T, Kajimoto Y, Kuratsune H, Kajimoto O, Watanabe Y: Antifatigue effects of coenzyme Q10 during physical fatigue. Nutrition 2008; 24(4):293-299.
  33. Hathcock JN, Shao A: Risk assessment for coenzyme Q10 (Ubiquinone). Regul Toxicol Pharmacol 2006; 45(3):282-288.
  34. Hidaka T, Fujii K, Funahashi I, Fukutomi N, Hosoe K: Safety assessment of coenzyme Q10 (CoQ10). Biofactors 2008; 32(1-4):199-208.
  35. Natural Medicines. Coenzyme Q-10 [online document]. Last updated on 14 February 2015. https://naturalmedicines.therapeuticresearch.com/databases/food,-herbs-supplements/professional.aspx?productid=938. Accessed on 8 March 2016
  36. Baggio E, Gandini R, Plancher AC, Passeri M, Carmosino G: Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. CoQ10 Drug Surveillance Investigators. Mol Aspects Med 1994; 15 Suppl:s287-s294.
  37. Feigin A, Kieburtz K, Como P, Hickey C, Claude K, Abwender D, Zimmerman C, Steinberg K, Shoulson I: Assessment of coenzyme Q10 tolerability in Huntington's disease. Mov Disord 1996; 11(3):321-323.
  38. uke C, Krikorian SA, Couris RR. Coenzyme Q10: A review of essential functions and clinical trials. US Pharm 2000;25:28-41.
  39. Greenlee H, Shaw J, Lau YK, Naini A, Maurer M: Lack of Effect of Coenzyme Q10 on Doxorubicin Cytotoxicity in Breast Cancer Cell Cultures. Integr Cancer Ther 2012; 11(3):243-250.
  40. Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994; 344(8933):1372-1373.
  41. Heck AM, DeWitt BA, Lukes AL: Potential interactions between alternative therapies and warfarin. Am J Health Syst Pharm 2000; 57(13):1221-1227.
  42. Porterfield LM: Why did the response to warfarin change? RN 2000; 63(12):107.
  43. Engelsen J, Nielsen JD, Hansen KF: [Effect of Coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial]. Ugeskr Laeger 2003; 165(18):1868-1871.
  44. Kaikkonen J, Nyyssonen K, Tuomainen TP, Ristonmaa U, Salonen JT: Determinants of plasma coenzyme Q10 in humans. FEBS Lett 1999; 443(2):163-166.
  45. Overvad K, Diamant B, Holm L, Holmer G, Mortensen SA, Stender S: Coenzyme Q10 in health and disease. Eur J Clin Nutr 1999; 53(10):764-770.
  46. ConsumerLab.com: Product Review: CoQ10 and Ubiquinol Supplements Review [online document], 7 March 2015. https://www.consumerlab.com/reviews/CoQ10-Ubiquinol-Supplements-Review/CoQ10. Accessed on 17 March 2016.